Hot Features
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for ... AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0093 | 1.30544637844 | 0.7124 | 0.787 | 0.7124 | 20823 | 0.74852169 | CS |
| 4 | -0.2065 | -22.2473604827 | 0.9282 | 0.9588 | 0.7008 | 61390 | 0.81183276 | CS |
| 12 | -0.4983 | -40.8442622951 | 1.22 | 1.3295 | 0.7008 | 92726 | 0.95183967 | CS |
| 26 | -0.0183 | -2.47297297297 | 0.74 | 1.45 | 0.6507 | 137196 | 1.04968085 | CS |
| 52 | 0.0235 | 3.36579776568 | 0.6982 | 1.45 | 0.6252 | 175854 | 0.9590565 | CS |
| 156 | -9.4183 | -92.882642998 | 10.14 | 17.17 | 0.0675 | 2083689 | 0.51442345 | CS |
| 260 | -9.4183 | -92.882642998 | 10.14 | 17.17 | 0.0675 | 2083689 | 0.51442345 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.